Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
US Stock MarketDetailed Quotes
ENSC Ensysce Biosciences
- 3.670
- +1.800+96.26%
Close Apr 23 16:00 ET
- 3.130
- -0.540-14.72%
Pre 08:06 ET
6.04MMarket Cap-0.62P/E (TTM)
4.850High3.260Low92.05MVolume4.230Open1.870Pre Close376.23MTurnover8102.82%Turnover RatioLossP/E (Static)1.64MShares14.67052wk High1.63P/B4.17MFloat Cap1.62052wk Low--Dividend TTM1.14MShs Float86364.000Historical High--Div YieldTTM85.03%Amplitude1.620Historical Low4.087Avg Price1Lot Size
About Ensysce Biosciences Company
Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company was founded in April 2003 and is headquartered in La Jolla, CA.
Company Profile
SymbolENSC
Company NameEnsysce Biosciences
Listing DateDec 29, 2017
Founded2003
CEODr. D. Lynn Kirkpatrick, PhD
MarketNASDAQ
Employees9
Fiscal Year Ends12-31
Address7946 Ivanhoe Avenue,Suite 201
CityLa Jolla
ProvinceCalifornia
CountryUnited States of America
Zip Code92037
Phone1-858-263-4196
Websitehttp://www.ensysce.com
Company Executives
- Name
- Position
- Salary
- Dr. D. Lynn Kirkpatrick, PhD
- President, Chief Executive Officer and Director
- 508.58K
- Linda Pestano, PhD
- Chief Development Officer
- --
- Geoffrey Birkett
- Chief Commercial Officer
- 392.35K
- David Humphrey, C.P.A.
- Chief Financial Officer, Principal Accounting Officer, Secretary and Treasurer
- 441.95K
- Dr. William K. Schmidt, PhD
- Chief Medical Officer
- --
- Dr. Jeffrey Millard, PhD
- Chief Operating Officer
- --
- Dr. Bob G. Gower, PhD
- Chairman of the Board
- 47.60K
- Lee Rauch
- Independent Director
- 29.17K
- William Chang
- Independent Director
- 30.10K
- Steve R. Martin
- Independent Director
- 32.92K
- Andrew Benton, J.D.
- Independent Director
- 30.10K
- Dr. Curtis Rosebraugh, M.D.
- Independent Director
- 25.42K
- Dr. Adam S. Levin, M.D.
- Independent Director
- 27.92K
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
